Hemcheck Sweden AB has signed a 3-month evaluation agreement, starting in March 2021, with potential continuation into a 24-month long distribution agreement with Medtech Corporation Trading (”Medtech Corporation”), one of the leading distributors of medical equipment in Qatar. The agreement is formed to evaluate the collaboration and market opportunity, and will be exclusive for the Qatari market, should the evaluation be successful according to both parties. Medtech Corporation has committed to an initial purchase order of readers and one-time tests for a value of 8,000 EUR, should the agreement be extended after the 3-month evaluation period.
– Medtech Corporation is well established in the Qatari market and they have shown a lot of interest in the potential of our products. We look forward to working with Medtech Corporation and hope that the collaboration will be long term and that the evaluation period will be successful, says Joen Averstad, CEO of Hemcheck.
– We are very satisfied that we have signed an evaluation agreement with Hemcheck. We will start the evaluations as soon as we can. We have high hopes for the success of the products in the Qatari market, and we look forward to the collaboration, says Dr M P Hassan Kunhi, CEO of Medtech Corporation.
For further information contact:
Hemcheck Sweden AB (publ)
Joen Averstad, CEO
Tel: +46 76 108 8191
About Medtech Corporation Trading
Medtech Corporation Trading was founded 40 years ago and has its head office in Doha in the state of Qatar, with additional offices in India, Saudi Arabia and the UAE. It’s one of the leading distributors of medical and laboratory equipment in Qatar. Medtech Corporation is a partner to global manufacturers such as Beckman Coulter, Instrumentation Laboratory, and Johnson-Johnson.
Read more at: https://www.med-tech.com/
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.
This information is such information that Hemcheck is required to disclose in accordance with the EU Market Abuse Regulation (MAR). The information was submitted, for publication by the above contact person, for publication on March 1, 2021 at 18.30